Compare Lucid Group Inc (LCID) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Sanofi SA — how do they compare? Lucid Group Inc trades at $6.52 (market cap $2.64B), while Sanofi SA trades at $43.74 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 39.5× Lucid Group Inc's market cap, and Sanofi SA pays a 5.55% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | SNY | |
|---|---|---|
Market Cap | $2.64B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.77 | $52.34 |
52-Week Low | $4.62 | $41.33 |
Enterprise Value | $5.54B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.47, down 2.12% on the day, reflecting ongoing investor concerns over persistent losses and cash burn. The stock exhibits a bearish technical trend with key support at $6, while fundamentally, the company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by a -249.21% net income margin. Recent news highlights an operational reset aiming for $1.4 billion in cash savings and a delayed midsize EV launch to 2027.
The outlook remains challenging with significant execution risks, though a $10.50 analyst price target suggests potential upside if cost-cutting and new initiatives like robotaxi partnerships succeed. High cash burn and competitive pressures pose substantial risks to near-term stability.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
